Sarah Hamidi, M.D., FRCPC
Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Associate Patient Safety Quality Officer, Department of Endocrine Neoplasia and HD, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2017 | University of Montreal, Montreal, QC, CA, Medicinae Doctorem (M.D.) |
| 2013 | University of Montreal, Montreal, QC, CA, Pre-medical Year |
Postgraduate Training
| 2022-2024 | Advanced clinical and research fellowship, Oncologic Endocrinology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2021-2022 | Chief Resident, Adult Endocrinology and Metabolism, The University of Montreal Hospital Center (CHUM), Montreal, QC |
| 2020-2022 | Clinical fellowship, Adult Endocrinology and Metabolism, University of Montreal, Montreal, QC |
| 2017-2020 | Clinical residency, Internal Medicine, University of Montreal, Montreal, QC |
Licenses & Certifications
| 2025 | Texas Medical License |
| 2025 | Texas Medical License |
| 2022 | Board Certification in Adult Endocrinology and Metabolism by the Royal College of Physicians and Surgeons of Canada |
| 2020 | Board Certification in Internal Medicine by the Royal College of Physicians and Surgeons of Canada |
Experience & Service
Faculty Academic Appointments
Attending Physician, The University of Montreal Hospital Center (CHUM), Montreal, QC, 2022 - 2022
Other Professional Positions
Clinical Research Scientist, Endocrinology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - 2025
Intramural Institutional Committee Activities
Co-chair, ALTER ATC: Adaptive Learning to improve Thyroid Cancer Responses in Anaplastic Thyroid Cancer, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, ACTION QI: Advanced Cancers of the Thyroid early Interrogation for Oncologic and Neoadjuvant Targets, The University of Texas MD Anderson Cancer Center, 2023 - Present
Co-leader, Safety Monitoring for Patients with Advanced Thyroid Cancer on Targeted Therapy, The University of Texas MD Anderson Cancer Center, 2022 - Present
Extramural Institutional Committee Activities
Member, Adult Endocrinology and Metabolism Fellowship Program Admissions Committee, University of Montreal, 2021
Member, Continuing Professional Development Committee of Quebec's Association of Endocrinologists, Quebec's Association of Endocrinologists, 2021 - 2022
Co-chair, Continuing Professional Development Committee of the Division of Endocrinology and Metabolism, The University of Montreal Hospital Center (CHUM), 2021 - 2022
Member, Well-being Committee of the Division of Endocrinology and Metabolism, The University of Montreal Hospital Center, 2020 - 2022
Honors & Awards
| 2025 | Travel Grant for the 2025 International Thyroid Congress American Thyroid Association, International Thyroid Congress American Thyroid Association |
| 2025 | Cyrus Scholar Award for Outstanding Clinical Research Award, The University of Texas MD Anderson Cancer Center |
| 2024 | 2024 Outstanding Trainee Poster Award, American Thyroid Association |
| 2024 | Ridgeway Trainee Travel Grant, American Thyroid Association |
| 2023 | 2023 Women Advancing Thyroid Research Award, American Thyroid Association |
| 2023 | Ridgeway Trainee Travel Grant, American Thyroid Association |
| 2023 | First place at the 2023 Division of Internal Medicine Research Retreat, Clinical Research poster session, The University of Texas MD Anderson Cancer Center |
| 2022 | Dean's Honor List - Postgraduate Medical Education, University of Montreal |
| 2022 | The Department of Medicine's Trainee Excellence Award, The University of Montreal Hospital Center (CHUM) |
| 2018 | Internal Medicine Resident Excellence Award, Maisonneuve-Rosemont Hospital, Montreal, QC |
| 2017 | Dean's Honor List - M.D, University of Montreal |
| 2012 | Highest Honors and Jury's Praise at the French Baccalaureate, Stanislas College, Montreal, QC |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2025. Addition of VEGF or mTOR Inhibition to BRAF-targeted Therapy in BRAFV600E-Mutated ATC (BRAFm-ATC). Poster. Peer-reviewed conference presentation (Presenter). Scottsdale, Arizona, US.
- 2024. Integrated Genomic Analysis Identifies Tumor Differentiation Status as a Crucial Determinant of Immune Infiltration and Potential Combinatorial Therapeutic Targets with Immunotherapy in Papillary Thyroid Carcinoma Patients. Conference. Chicago, IL, US.
- 2024. Characterization of RAS-mutant Anaplastic Thyroid Carcinoma. Poster. Chicago, IL, US.
- 2024. Clinicopathological Features of Advanced, RAS-driven Differentiated Thyroid Carcinoma. Poster. Chicago, IL, US.
- 2024. Efficacy and Safety of Selective RET Inhibitors in Hereditary Medullary Thyroid Carcinoma. Poster. Chicago, IL, US.
- 2024. Atezolizumab Plus Taxane Chemotherapy for the Treatment of Non-BRAF, Non-RAS Mutated Anaplastic Thyroid Carcinoma: Final Analysis. Poster. Chicago, IL, US.
- 2023. Efficacy of Adding Anti-PD1 Immunotherapy To Dabrafenib + Trametinib at Progression in BRAFV600E Mutated Anaplastic Thyroid Carcinoma. Poster. San Diego, CA, US.
- 2023. Checkpoint Inhibition in Addition to Dabrafenib + Trametinib for BRAF V600E-mutated Anaplastic Thyroid Cancer. Conference. Washington, D.C, US.
- 2022. Thyroid Paraganglioma, a Very Rare Condition: Case Report and Review of the Literature. Poster. Montreal, QC, CA.
- 2022. Use of Thyroglobulin in the Follow-up of Low-Risk Differentiated Thyroid Cancers Treated Without Radioiodine Remnant Ablation. Poster. Montreal, QC, CA.
- 2021. Real-life Experience with Lenvatinib Treatment of Advanced Thyroid Cancers from a Canadian Quaternary Care Center: Safety, Efficacy and Some Rare Side Effects. Poster. Virtual, US.
- 2021. Gastrointestinal Stromal Tumor Mimicking an Adrenal Incidentaloma: A Case Report. Poster. Virtual, US.
- 2019. Is There an Optimal Timing for Performing Post-Therapy Whole Body Scans After Radioiodine Treatment of Differentiated Thyroid Cancers?. Poster. Chicago, IL, US.
International Presentations
- 2025. The Genomic Landscape of Medullary Thyroid Carcinoma Identified by the Afirma RNA-Sequencing Classifier: Insights from a Large Real-World Cohort. Poster. 17th International Thyroid Conference (ITC). Rio de Janeiro, BR.
- 2024. Efficacy of Adding Lenvatinib to BRAF-directed Therapy at Progression in BRAFV600E-mutated Anaplastic Thyroid Carcinoma. Poster. Athens, GR.
- 2023. Efficacy and Safety of Selective RET-inhibitors in Hereditary Medullary Thyroid Carcinoma: A Real-World Experience. Conference. Marseille, FR.
Formal Peers
- 2025. The Basics of Clinical research in Oncologic Endocrinology. Houston, Texas, US.
- 2025. Thyroid Cancer: An Overview. Puerto Rico, PR.
- 2024. Management of Anaplastic Thyroid Cancer in 2024. Houston, Texas, US.
- 2024. Current and Future Therapies for Advanced Thyroid Cancers. Houston, Texas, US.
Grant & Contract Support
| Date: | 2025 - Present |
| Title: | Neoadjuvant Treatment with Zanzalintinib for Advanced Thyroid Cancer |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-PI |
| Date: | 2025 - Present |
| Title: | Identifying Biomarkers of Response to Radiation-Enhanced Checkpoint Blockade in non-BRAF mutated Anaplastic Thyroid Cancer |
| Funding Source: | U-Pilot Award by the U Foundation |
| Role: | Co-PI |
| Date: | 2024 - Present |
| Title: | Applying the Neoadjuvant Strategy to Non-BRAF Mutated Anaplastic Thyroid Carcinoma |
| Funding Source: | MD Anderson, Dept. of Head & Neck Surgery, ATC Multidisciplinary Petrick Research Program |
| Role: | Co-PI |
| Date: | 2024 |
| Title: | Association of the Thyroid Differentiation Score with Tumor Metabolism and Immune Phenotype |
| Funding Source: | Endocrine Fellows Foundation |
| Role: | Co-PI |
Selected Publications
Peer-Reviewed Articles
- Hamidi S, Bandi AV, Hamidi S, Iyer P, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Waguespack SG, Basmaci UN, Williams MD, Mansour M, Monroe MG, Gross ND, Goepfert RP, Perrier ND, Banuchi V, Wang JR, Maniakas A, Zafereo ME. Management of Retropharyngeal Lymph Node Metastases in Thyroid Cancer. Head and Neck Journal of the Sciences and Specialties of the Head and Neck, 2025. e-Pub 2025.
- Hawes EE, Banuchi VE, Maniakas A, Wang JR, Graham PH, Diersing JD, Busaidy NL, Cabanillas ME, Dadu R, Hamidi S, Iyer P, Waguespack SG, Ahmed S, Alizada S, Belcastro A, Alsharif R, Hu MI, Zafereo ME. Partial Laryngectomy for Thyroid Cancer: A Single Institution Case Series With Operative Techniques. Head Neck, 2025. e-Pub 2025. PMID: 40747656.
- Cabanillas, ME, Busaidy, NL, Gunn, GB, Iyer, PC, Ferrarotto, R, Gule-Monroe, MK, Maniakas, A, Williams, MD, Liu, S, Fellman, B, Spiotto, MT, Hamidi, S, Akhave, NS, Lee, A, Wang, RJ, De Sousa, LG, Marczyk, VR, Zafereo, M, Dadu, R. Adjuvant Pembrolizumab after Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid Cancer. Thyroid 35(7):763-770, 2025. e-Pub 2025. PMID: 40609521.
- Hamidi S, Maniakas A, Akhave NS, Banuchi VE, Busaidy NL, Dadu R, Ferrarotto R, Guise TA, Hofmann M, Hosseini S, Hu MI, Iyer PC, Mansour M, Marczyk VR, Roy-Chowdhuri S, Sherman SI, Sousa LG, Wang JR, Williams MD, Zafereo ME, Waguespack SG, Cabanillas ME. Characterization of Advanced RAS-driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues. The Journal of Clinical Endocrinology & Metabolism, 2025. e-Pub 2025.
- Hamidi, S, Dadu, R, Iyer, PC, Busaidy, NL, Maniakas, A, Wang, RJ, Banuchi, VE, Hosseini, SM, Williams, MD, Zafereo, M, Cabanillas, ME. Circulating Tumor DNA as a Biomarker for Disease Surveillance in Anaplastic Thyroid Cancer. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 40570261.
- Cabanillas, ME, Akhave, NS, Banuchi, VE, Busaidy, NL, Dadu, R, Ferrarotto, R, Gunn, GB, Hamidi, S, Hofmann, M, Hosseini, SM, Iyer, PC, Lai, SY, Lee, A, Maniakas, A, Ning, M, Spiotto, MT, Wang, RJ, Williams, MD, Zafereo, M. Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer. Thyroid 35(5):462-470, 2025. e-Pub 2025. PMID: 40388579.
- Marczyk, VR, Fazeli, S, Dadu, R, Busaidy, NL, Iyer, PC, Hu, MI, Sherman, SI, Hamidi, S, Hosseini, SM, Williams, MD, Ahmed, S, Routbort, MJ, Luthra, R, Roy Chowdhuri, S, San Lucas, FA, Patel, KP, Hong, DS, Zafereo, M, Wang, RJ, Maniakas, A, Waguespack, SG, Cabanillas, ME. NTRK Fusion-Positive Thyroid Carcinoma. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 39983078.
- Hamidi S, Ning MS, Phan J, Zafereo ME, Gule-Monroe MK, Dadu R. Recurrent Poorly Differentiated Thyroid Cancer Successfully Treated With Radiation and Immunotherapy. JCEM Case Rep 3(2), 2025. e-Pub 2025.
- Dudzinski, SO, Cabanillas, ME, Hamidi, S, Marczyk, VR, Busaidy, NL, Dadu, R, Welsh, J, Hu, MI, Gunn, GB, Wang, C, Waguespack, SG, Phan, J, Beckham, TH, Chang, JY, Sherman, SI, Reddy, JP, Ying, AK, O'Reilly, M, Chen, A, Lee, A, Gandhi, S, Liao, Z, Ludmir, EB, Nguyen, Q, Lin, SH, Zafereo, M, Ning, M. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer. JNCCN Journal of the National Comprehensive Cancer Network 23(1), 2025. e-Pub 2025. PMID: 39662038.
- Hamidi, S, Yedururi, S, Hu, MI, Busaidy, NL, Sherman, SI, Jimenez, C, Grubbs, EG, Maniakas, A, Zafereo, M, Subbiah, V, Waguespack, SG. Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma. Thyroid 35(1):6-17, 2025. e-Pub 2025. PMID: 39630530.
- Hamidi S, Dadu R, Zafereo ME, Wang JR, Roy-Chowdhuri S, Williams MD, Hosseini S, Ferrarotto R, Akhave NS, Sousa LG, Iyer PC, Marczyk VR, Guise TA, Hofmann MC, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Maniakas A, Cabanillas ME. RAS-mutant follicular-derived advanced thyroid cancers: current knowledge and future avenues. e-Pub 2024.
- Hamidi S, Zafereo ME, Wang JR, Maniakas A, Busaidy NL, Dadu R, Iyer PC, Cabanillas ME. Circulating Tumor DNA as a Biomarker for Disease surveillance in Anaplastic Thyroid Cancer. JCO Precis Oncol. e-Pub 2024.
- Hamidi S, Mahvash A, Hu MI. Paraneoplastic Diarrhea From Medullary Thyroid Carcinoma Resolved With Yttrium-90 Radioembolization of Liver Metastases. JCEM Case Rep 2(8), 2024. e-Pub 2024. PMID: 39076377.
- Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME, Wang JR, Busaidy NL, Cabanillas ME. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid 34(3):336-346, 2024. e-Pub 2024. PMID: 38226606.
- Hamidi S, Boucher A, Lemieux B, Rondeau G, Lebœuf R, Ste-Marie L, Le XK, Mircescu H. Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects. J Endocr Soc 6(6), 2022. e-Pub 2022. PMID: 35475024.
- Hamidi S, Mottard S, Berthiaume MJ, Doyon J, Bégin MJ, Bondaz L. Brown tumor of the iliac crest initially misdiagnosed as a giant cell tumor of the bone. Endocrinol Diabetes Metab Case Rep, 2020. e-Pub 2020. PMID: 32478667.
Invited Articles
- Shariq OA, Waguespack SG, Hamidi S, Kensing BC, Hu MI, Skefos CM, Perrier ND. Approach to the Patient: Hereditary Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 110(9):2685-2697, 2025. e-Pub 2025. PMID: 40105880.
- Hamidi S, Maniakas A. Recent advances in anaplastic thyroid cancer management. Curr Opin Endocrinol Diabetes Obes 30(5):259-264, 2023. e-Pub 2023. PMID: 37410453.
Review Articles
- Hamidi, S, Maniakas, A, Cabanillas, ME. Advances in Anaplastic Thyroid Cancer Treatment. Endocrinology and Metabolism Clinics of North America 54(3):361-375, 2025. e-Pub 2025. PMID: 40716892.
- Hamidi S, Maniakas A, Cabanillas ME. Advances in Anaplastic Thyroid Cancer Treatment. Endocrinol Metab Clin North Am 54(3):361-375, 2025. e-Pub 2025. PMID: 40716892.
- Keam S, Turner N, Kugeratski FG, Rico R, Colunga-Minutti J, Poojary R, Alekseev S, Patel AB, Li YJ, Sheshadri A, Loghin ME, Woodman K, Aaroe AE, Hamidi S, Iyer PC, Palaskas NL, Wang Y, Nurieva R. Toxicity in the era of immune checkpoint inhibitor therapy. Front Immunol 15, 2024. e-Pub 2024.
- Hamidi S, Turner N, Ouni R, Rico R, Henderson YC, Puche M, Alekseev S, Colunga-Minutti JG, Zafereo ME, Lai SY, Kim ST, Cabanillas ME, Nurieva R. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy. Front Immunol 15, 2024. e-Pub 2024. PMID: 38868771.
- Hamidi S, Hu MI. RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions. Ann Endocrinol (Paris) 85(2):118-126, 2024. e-Pub 2024. PMID: 38342224.
- Keam, S, Turner, N, Grande Kugeratski, F, Rico, R, Colunga-Minutti, JG, Poojary, R, Alekseev, S, Patel, A, Li, YJ, Sheshadri, A, Loghin, ME, Woodman, K, Aaroe, AE, Hamidi, S, Iyer, PC, Palaskas, NL, Wang, Y, Nurieva, R. Toxicity in the era of immune checkpoint inhibitor therapy. Frontiers in immunology 15, 2024. e-Pub 2024. PMID: 39247203.
- Hamidi S, Hofmann M, Iyer PC, Cabanillas ME, Hu MI, Busaidy NL, Dadu R. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. Front Endocrinol (Lausanne) 14, 2023. e-Pub 2023. PMID: 37435488.
Other Articles
- Salim HA, Msherghi A, Learned K, Zafereo M, Wang J, Dagher SA, Altintas Taslicay C, Dagher R, Alizada S, Hu MI, Cabanillas ME, Busaidy N, Hamidi S, Tawbi H, Li J, Ucisik FE, Wintermark M Prognostic Factors in Thyroid Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis. Thyroid, 2025. PMID: 40956665.
- Marczyk, VR, Fazeli, S, Dadu, R, Busaidy, NL, Iyer, PC, Hu, MI, Sherman, SI, Hamidi, S, Hosseini, SM, Williams, MD, Ahmed, S, Routbort, MJ, Luthra, R, Roy Chowdhuri, S, San Lucas, FA, Patel, KP, Hong, DS, Zafereo, M, Wang, RJ, Maniakas, A, Waguespack, SG, Cabanillas, ME Erratum. JCO Precision Oncology 9, 2025. PMID: 40632979.
- Hamidi S, Dadu R, Zafereo ME, Ferrarotto R, Wang JR, Maniakas A, Gunn G, Lee A, Spiotto MT, Iyer PC, Sousa LG, Akhave NS, Ahmed S, Learned KO, Lu C, Lai SY, Williams M, Hosseini S, Busaidy NL, Cabanillas ME Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement. JAMA Oncol, 2024. PMID: 38990526.
Abstracts
- Marczyk VR, Hamidi S, Zafereo M, Waguespack SG, Dadu R, Busaidy NL, Iyer PC, Maniakas A, Banuchi V, Cabanillas ME, Wang JR. Characterization Of The Genomic Landscape Of BRAF-, RAS-, And Fusion-Negative Thyroid Carcinomas Underscores The Role Of Tumor Suppressor Genes Available. 17th International Thyroid Congress Scientific Program, 2025. e-Pub 2025.
- Iyer PC, Wang JR, Hamidi S, Busaidy NL, Ferrarotto R, Akhave NS, Sousa LG, Gunn GB, Spiotto MT, Huang Q, Cabanillas ME. GRASSROOT- Global Real-world data in patients with Advanced thyroid cancer on Standard of care and Specialized Interventions- Registry of Oncologic Outcomes with Testing and treatment. e-Pub 2024.
- Houl JH, Mendez PM, Wang JR, Hamidi S, Maniakas A, Iyer PC, Lai SY, Cabanillas M, Busaidy NL, Dadu R, Zafereo M, Hofmann AM. Targeting the MAPK and DNA Repair Pathways in Poorly Differentiated and Anaplastic Thyroid Cancer Cells. 2024 American Thyroid Association Annual Meeting. e-Pub 2024.
- Abubaker A, Henderson Y, Wang JR, Zafereo M, Banuchi V, Goswami M, Cabanillas ME, Busaidy N, Dadu R, Iyer P, Hamidi S, Williams M, Hosseini S, Lai SY, Maniakas A. Challenges and factors affecting successful patient-derived xenograft model establishment for anaplastic thyroid cancer. 2024 American Thyroid Association Annual Meeting. e-Pub 2024.
- Marczyk VR, Hamidi S, Cabanillas ME. Identification of Somatic Events Associated with Anaplastic Transformation in BRAFV600E-driven Thyroid Carcinomas: NGS Profiling of 1,000 Thyroid Cancers. 2024 American Thyroid Association Annual Meeting. e-Pub 2024.
- Abdallah D, Hamidi S, Dadu R, Busaidy NL, Iyer PC, Waguespack SG, Zafereo ME, Cabanillas ME. Fusion-Driven Anaplastic Thyroid Cancer (ATC): Characterization and Clinical Outcomes. 2024 American Thyroid Association Annual Meeting. e-Pub 2024.
- Ramos HE, Hamidi S, Faria SC, Dadu R, Hu MI, Busaidy NL, Waguespack SG, Weitzman S, Sherman SI, Cabanillas ME. Redifferentiation therapy (RDT) in differentiated thyroid carcinomas (DTC): Real-World data of a large cohort of patients. 2024 American Thyroid Association Annual Meeting, 2024. e-Pub 2024.
- Cubb TD, Hamidi S, Gule-Monroe MK, Busaidy NL, Iyer PC, Shaw KR, Roy-Chowdhuri S, Sura GH, Zafereo ME, Wang JR, Banuchi VE, Maniakas A, Cabanillas ME. Effect of PI3K Pathway Activating Mutations (PI3Kpath-mutation) on Response to BRAF/MEK Inhibitor (BRAF/MEKi) Therapy in BRAFV600E Mutated Anaplastic Thyroid Cancer (BRAFV600Em-ATC), 2024. e-Pub 2024.
- Cabanillas ME, Busaidy NL, Iyer PC, Gule-Monroe M, Gunn GB, Spiotto MT, Akhave N, Sousa L, Ferrarotto R, Zafereo ME, Wang RJ, Maniakas A, Liu S, Fellman B, Hamidi S, Dadu R. Adjuvant pembrolizumab (pembro) after multimodal therapy for anaplastic thyroid cancer (ATC). 2024 American Thyroid Association Annual Meeting, 2024. e-Pub 2024.
- Ning M, Dudzinski S, Busaidy N, Dadu R, Welsh J, Hu M, Hamidi S, Marczyk VR, Gunn B, Wang C, Waguespack S, Phan J, Beckham T, Chang J, Sherman S, Reddy J, Ying A, O'Reilly M, Chen A, Lee A, Gandhi S, Liao Z, Ludmir E, Nguyen Q, Tang C, Lin S, Zafereo M, Cabanillas M. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Differentiated Thyroid Carcinoma: A Potential Strategy to Defer Escalation of Systemic Therapy. 2023 American Thyroid Association Annual Meeting 33(S1), 2023. e-Pub 2023.
- Castellanos LE, Hamidi S, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Iyer PC, Roy-Chowdhuri S, Sherman SI, Sura G, Wang JR, Williams MD, Iorgulescu JB, Waguespack SG. RAF Family Fusions in Thyroid Carcinomas: Clinicopathological Analysis of 16 Patients. 2024 American Thyroid Association Annual Meeting.
- Ning MS, Dudzinski SO, Busaidy NL, Dadu R, Hamidi S, Welsh J, Gunn B, Waguespack SG, Hu MI, Marczyk VR, Spiotto M, Phan J, Reddy JP, Lee A, Ludmir EB, Maniakas A, Iyer P, Beckham T, Zafereo MA, E Cabanillas AM. Consolidative radiotherapy for oligometastatic and oligoprogressive anaplastic thyroid carcinoma: the potential utility of local therapy for limited distant sites. 2024 American Thyroid Association Annual Meeting.
- Houl JH, Yarmand R, Mendez PM, Henderson Y, Wang JR, Hamidi S, Maniakas A, Iyer PC, Lai SY, Cabanillas M, Busaidy NL, Dadu R, Zafereo M, Hofmann AM. Role of ETV5/p38 signaling Axis in BRAF-Mutated. 2024 American Thyroid Association Annual Meeting.
- Marczyk VR, Wu CC, Hamidi S, Loberg MA, Thennavan A, Henderson Y, Sheng Q, Williams MD, Zafereo ME, Cabanillas ME, Lai SY, Huang E, Navin N, Weiss VL, Wang JR. A Tumor-Cell Specific Gene Signature Derived From Single-Cell Sequencing Is Prognostic Across Independent Cohorts Of Papillary Thyroid Carcinoma Patients. 17th International Thyroid Congress Scientific Program.
- Fournier I, Waguespack SG, Castellanos L, Iyer P, Hamidi S, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Williams MD, Palacios JA, Monroe MG, Banuchi VE, Wang JR, Maniakas A, Zafereo ME. Neoadjuvant Larotrectinib Before Surgery For NTRK Fusion-Positive Thyroid Cancer: A Case Series. 17th International Thyroid Congress Scientific Program.
- Fournier I, Jorge Eduardo AP, Mahmoud Innab MK, Zafereo ME, Wang JR, Gross ND, Lango MN, Goepfert RP, Sturgis EM, Grubbs EG, Graham PH, Gupta SK, Busaidy NL, Cabanillas ME, Dadu R, Hamidi S, Hu MI, Iyer P, Waguespack S, Ahmed S, Kwon M, Banuchi VE, Maniakas A, Hosseini SM, Williams MD. Prognostic Significance of BRAFV600E Status In Patients Diagnosed With Papillary Thyroid Cancer (PTC). 17th International Thyroid Congress Scientific Program.
- Cubb T, Iyer P, Roecker Z, Sood A, Jazaeri A, Ramalingam P, Hamidi S, Dadu R, Ying A, Busaidy N, Waguespack S, Hu M, Sherman S, Cabanillas M. Malignant Struma Ovarii (MSO) Clinical Characteristics And Outcomes: A Retrospective Tertiary Cancer Center Experience. 17th International Thyroid Congress Scientific Program.
Letters to the Editor
- Matrone A, Kroiss M, Gild ML, Hamidi S, Sayehli CM, Siddal R, Gambale C, Prete A, Hu MI, Robinson BG, Elisei R. Erectile Dysfunction in Patients Treated with Selpercatinib for RET-Altered Thyroid Cancer. Thyroid, 2024.
Patient Reviews
CV information above last modified November 18, 2025